Endocannabinoid signaling in social functioning: an RDoC perspective.
Core deficits in social functioning are associated with various neuropsychiatric and neurodevelopmental disorders, yet biomarker identification and the development of effective pharmacological interventions has been limited. Recent data suggest the intriguing possibility that endogenous cannabinoids, a class of lipid neuromodulators generally implicated in the regulation of neurotransmitter release, may contribute to species-typical social functioning. Systematic study of the endogenous cannabinoid signaling could, therefore, yield novel approaches to understand the neurobiological underpinnings of atypical social functioning. This article provides a critical review of the major components of the endogenous cannabinoid system (for example, primary receptors and effectors-Δ9-tetrahydrocannabinol, cannabidiol, anandamide and 2-arachidonoylglycerol) and the contributions of cannabinoid signaling to social functioning. Data are evaluated in the context of Research Domain Criteria constructs (for example, anxiety, chronic stress, reward learning, motivation, declarative and working memory, affiliation and attachment, and social communication) to enable interrogation of endogenous cannabinoid signaling in social functioning across diagnostic categories. The empirical evidence reviewed strongly supports the role for dysregulated cannabinoid signaling in the pathophysiology of social functioning deficits observed in brain disorders, such as autism spectrum disorder, schizophrenia, major depressive disorder, posttraumatic stress disorder and bipolar disorder. Moreover, these findings indicate that the endogenous cannabinoid system holds exceptional promise as a biological marker of, and potential treatment target for, neuropsychiatric and neurodevelopmental disorders characterized by impairments in social functioning.
Center for Interdisciplinary Brain Sciences Research, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.|Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.
D S
DS
Karhson
Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.
A Y
AY
Hardan
Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.
K J
KJ
Parker
Brain Res. 2000 Feb 28;857(1-2):151-7
10700562
Learn Mem. 2000 May-Jun;7(3):132-9
10837502
Nat Rev Neurosci. 2000 Oct;1(1):41-50
11252767
J Pharmacol Exp Ther. 2001 Apr;297(1):189-97
11259544
Nature. 2001 Oct 4;413(6855):519-23
11586359
Pharmacol Rev. 2002 Jun;54(2):161-202
12037135
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10819-24
12136125
Nat Med. 2003 Jan;9(1):76-81
12461523
Curr Opin Chem Biol. 2003 Aug;7(4):469-75
12941421
Nat Rev Neurosci. 2003 Oct;4(10):829-39
14523382
J Physiol. 2005 Dec 15;569(Pt 3):751-60
16239276
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18620-5
16352709
Handb Exp Pharmacol. 2005;(168):299-325
16596779
Trends Neurosci. 1990 Oct;13(10):420-3
1700516
Psychopharmacology (Berl). 2008 Apr;197(2):217-27
18058088
Eur Neuropsychopharmacol. 2008 Jul;18(7):519-30
18434104
Prog Brain Res. 2008;170:397-432
18655899
Front Mol Neurosci. 2008 Mar 28;1:2
18946535
J Pharmacol Exp Ther. 2009 Jan;328(1):343-50
18948500
Science. 2008 Nov 7;322(5903):900-4
18988842
Expert Rev Mol Med. 2009 Jan 20;11:e3
19152719
Curr Drug Abuse Rev. 2009 Jan;2(1):51-75
19630737
Neuropsychopharmacology. 2009 Dec;34(13):2733-45
19710634
Horm Behav. 2010 Jun;58(1):100-10
19819241
J Neurosci. 1991 Feb;11(2):563-83
1992016
Dev Neurobiol. 2010 Feb 15;70(3):195-203
20017118
Neuroscience. 2010 Jun 30;168(2):371-86
20394803
Br J Pharmacol. 2010 Jun;160(3):467-79
20590558
Am J Psychiatry. 2010 Jul;167(7):748-51
20595427
Trends Pharmacol Sci. 2010 Oct;31(10):463-9
20684996
J Neurosci. 2010 Nov 10;30(45):14980-6
21068301
Biofactors. 2011 Jan-Feb;37(1):1-7
21328621
Stress. 2011 Jul;14(4):398-406
21663538
Br J Pharmacol. 2011 Aug;163(7):1344-64
21749363
Neuropharmacology. 2011 Oct-Nov;61(5-6):1016-25
21767554
Br J Pharmacol. 2012 Feb;165(4):951-64
21838753
Behav Brain Res. 2012 Jan 15;226(2):481-92
22020200
Neuroscience. 2012 Mar 1;204:5-16
22214537
Recent Pat CNS Drug Discov. 2012 Apr 1;7(1):25-40
22280339
Mayo Clin Proc. 2012 Feb;87(2):107-9
22305022
Trends Cogn Sci. 2012 Apr;16(4):231-9
22425667
Front Behav Neurosci. 2012 Mar 14;6:9
22457644
Brain Struct Funct. 2013 May;218(3):669-82
22555958
Annu Rev Psychol. 2013;64:21-47
22804774
ACS Chem Neurosci. 2012 May 16;3(5):369-78
22860205
Neuron. 2012 Oct 4;76(1):70-81
23040807
J Neurosci. 2012 Oct 24;32(43):14899-908
23100412
Rev Neurosci. 2012;23(5-6):707-22
23104854
Neuron. 2013 May 8;78(3):498-509
23583622
Behav Brain Res. 2013 Jul 15;249:124-32
23643692
PLoS One. 2013 Jun 19;8(6):e66387
23840456
J Neuroendocrinol. 2013 Oct;25(10):898-909
23895426
PLoS One. 2013 Jul 31;8(7):e70074
23936144
J Neurosci. 2013 Sep 18;33(38):15022-31
24048832
Nat Rev Neurosci. 2013 Nov;14(11):810-4
24135697
Dev Psychobiol. 2014 Jul;56(5):1017-26
24271510
J Psychiatr Res. 2014 Apr;51:30-6
24405552
Am J Psychiatry. 2014 Apr;171(4):395-7
24687194
Neurosci Biobehav Rev. 2014 Jun;43:199-212
24726578
Pflugers Arch. 2015 Jul;467(7):1551-1564
25081244
Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):12258-63
25092315
Mol Pharmacol. 2014 Oct;86(4):430-7
25106425
Front Psychiatry. 2014 Jul 31;5:92
25132823
Nat Rev Neurosci. 2014 Nov;15(11):757-64
25315390
Mol Psychiatry. 2015 Sep;20(9):1085-90
25349162
Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):E5007-15
25368177
Sci Rep. 2015 Jan 06;5:7642
25560837
J Biol Chem. 2015 Apr 3;290(14):8711-21
25666611
Nat Rev Neurosci. 2015 May;16(5):290-304
25891510
Behav Brain Res. 2015 Sep 15;291:164-171
25979787
Nat Rev Neurosci. 2015 Jun;16(6):317-31
25991441
Neuropsychopharmacology. 2016 Jan;41(1):80-102
26068727
Neurobiol Learn Mem. 2015 Nov;125:1-14
26092091
Neurosci Biobehav Rev. 2015 Nov;58:79-91
26116544
Neuropsychopharmacology. 2016 Feb;41(3):858-68
26174597
Neurotherapeutics. 2015 Oct;12(4):837-47
26216231
Nat Rev Neurosci. 2015 Oct;16(10):579-94
26373473
Nature. 2015 Sep 24;525(7570):519-22
26375004
Nat Neurosci. 2015 Oct;18(10):1394-404
26404714
Front Neurosci. 2015 Sep 24;9:335
26441508
Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):14084-9
26504214
Psychopharmacology (Berl). 2016 May;233(10):1879-88
26558620
Nat Rev Neurosci. 2015 Dec;16(12):705-18
26585799
Int Rev Neurobiol. 2015;125:257-302
26638769
Pflugers Arch. 2016 Apr;468(4):727-37
26739712
Pharmaceuticals (Basel). 2010 Aug 10;3(8):2517-2553
27713365
Mol Pharmacol. 1988 Nov;34(5):605-13
2848184
Cannabis Cannabinoid Res. 2016 Feb 01;1(1):81-89
28861483
Psychopharmacologia. 1973 Oct 23;33(1):53-70
4358666
Nature. 1993 Sep 2;365(6441):61-5
7689702
Eur J Pharmacol. 1996 Oct 10;313(1-2):43-9
8905327
Eur J Pharmacol. 1998 Jul 17;353(1):23-31
9721036
Neurobiol Dis. 1998 Dec;5(6 Pt B):474-82
9974179